Evaluation and management of hyperlipidemia in children and adolescents

Current Opinion in Pediatrics

Volumn 22, Issue 4, 2010, Pages 485-493

  Iughetti, Lorenzo ^a   Bruzzi, Patrizia ^a   Predieri, Barbara ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitors (statins); children; Ezetimibe; hyperlipidemia; lipid lowering therapy

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BEZAFIBRATE; BILE ACID; BILE ACID SEQUESTRANT; CHOLESTEROL ESTER; CIPROFIBRATE; COLESEVELAM; COLESTILAN; COLESTIPOL; COLESTYRAMINE; CYTOKINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EZETIMIBE; FATTY ACID; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; SIMVASTATIN; SOYBEAN PROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; CHOLESTEROL;

ADOLESCENT; ADULT; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHILD; CHILD HEALTH; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL EVALUATION; CLINICAL FEATURE; CYTOKINE RELEASE; DAIRY PRODUCT; DIAGNOSTIC PROCEDURE; DIET; DRUG ABSORPTION; DRUG BINDING; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG TOLERABILITY; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FISH; FLUSHING; FOOD INTAKE; FRUIT; GENETIC DISORDER; GLUCOSE INTOLERANCE; HUMAN; HYPERLIPIDEMIA; HYPERURICEMIA; LIFESTYLE MODIFICATION; LIPID METABOLISM; LIPID PEROXIDATION; LIVER FAILURE; MORBIDITY; MORTALITY; MYOPATHY; OXIDATIVE STRESS; PATIENT CARE; PREVENTION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; TERATOGENESIS; TREATMENT CONTRAINDICATION; VEGETABLE; BLOOD; HYPERLIPIDEMIAS; LIFESTYLE; PROGNOSIS;

ADOLESCENT; ANTILIPEMIC AGENTS; CHILD; CHOLESTEROL; HUMANS; HYPERLIPIDEMIAS; LIFE STYLE; PROGNOSIS; HYPOLIPIDEMIC AGENTS;

EID: 77955229361     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e32833ab869     Document Type: Review

References (70)

1. Frontini MG, Srinivasan SR, Xu J, et al. Usefulness of childhood nonhigh density lipoprotein cholesterol levels versus other lipoprotein measures in predicting adult subclinical atherosclerosis: the Bogalusa Heart Study. Pediatrics 2008; 121:924-929.
2. Raitakari OT, Juonala M, Kahonen M, et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the cardiovascular risk in young Finns study. JAMA 2003; 290:2277-2283.
3. Johnson HM, Douglas PS, Srinivasan SR, et al. Predictors of carotid intima-media thickness progression in young adults: the Bogalusa Heart Study. Stroke 2007; 38:900-905.
4. McGill HC, McMahan CA, Gidding SS. Are pediatricians responsible for prevention of adult cardiovascular disease? Nat Clin Pract 2009; 6:10-11.
5. McGill HC, McMahan A, Gidding SS. Preventing heart disease in the 21st century: implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Study. Circulation 2008; 117:1216-1227.
6. Viikari J, Niinikoski H, Raitakari OT, Simell O. The initiatives and outcomes for cardiovascular risks that can be achieved through paediatric counselling. Curr Opin Lipidol 2009; 20:17-23.
7. Juonala M, Viikari J, Ronnemaa T, et al. Association of dyslipidemias from childhood to adulthood with carotid intima-media thickness, elasticity and brachial flow-mediated dilatation in adulthood. Arterioscler Thromb Vasc Biol 2008; 28:1012-1017.
8. Ford ES, Li C, Zhao G, Mokdad AH. Concentrations of low-density lipoprotein cholesterol and total cholesterol among children and adolescents in the United States. Circulation 2009; 119:1108-1115.
9. National Cholesterol Education Program. Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 1992; 89 (Suppl):525-584.
10. McCrindle BW, Urbina EM, Dennison BA, et al. American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee; American Heart Association Council of Cardiovascular Disease in the Young, American Heart Association Council on Cardiovascular Nursing. Drug therapy of highrisk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 2007; 115:1948-1967.
11. Daniels SR, Greer FR, Committee on Nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics 2008; 122:198-208.
12. Kavey RW, Allada V, Daniels SR, et al. Cardiovascular risk reduction in high risk pediatric patients. A scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and Kidney in Heart Disease; the interdisciplinary Working Group on Quality of Care and outcomes Research. Circulation 2006; 114:2710-2738.
13. Magnussen CG, Raitakari OT, Thomson R, et al. Utility of currently recommended pediatric dyslipidemia classifications in predicting dyslipidemia in adulthood: evidence from the Childhood Determinants of Adult Health (CDAH) study, Cardiovascular Risk in Young Finns Study, and Bogalusa Heart Study. Circulation 2008; 117:32-42.
14. Mousavi SA, Berge KE, Leren TP. The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis. J Intern Med 2009; 266:507-519.
15. Vasan RS, Pencina MJ, Robins SJ, et al. Association of circulating cholesteryl ester transfer protein activity with the incidence of cardiovascular disease in the community. Circulation 2009; 299:2777-2788.
16. Shah PK. The Yin and Yang of cholesteryl ester transfer protein in cardiovascular disease. Circulation 2009; 120:2408-2410.
17. Tabas I. Consequences of cellular cholesterol accumulation: basic concepts and physiological implications. J Clin Invest 2002; 110:905-911.
18. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis. J Am Coll Cardiol 2009; 54:2129-2138.
19. Tonstad S, Joakimsen O, Stensland-Bugge E, et al. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects. Arterioscler Thromb Vasc Biol 1996; 16:984-991.
20. de Jongh S, Lilien MR, Bakker HD, et al. Familial history of cardiovascular events and endothelial dysfunction in children with familial hypercholesterolemia. Atherosclerosis 2002; 163:193-197. (Pubitemid 34615743)
21. Wiegman A, de Groot E, Hutten BA, et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolemia. Lancet 2004; 363:369-370.
22. Morrison KM, Dyal L, Conner W, et al. Cardiovascular risk factors and noninvasive assessment of subclinical atherosclerosis in youth. Atherosclerosis 2010; 208:501-505.
23. Le J, Zhang D, Menees S, et al. Vascular age is advanced in children with atherosclerosis-promoting risk factors. Circ Cardiovasc Imaging 2010; 3:8-14.
24. Miettinen TA, Hallikainen M, Raitakari OT, et al. Twenty-one year tracking of serum noncholesterol sterol. The Cardiovascular Risk in Young Finns study. Nutr Metab Cardiovasc Dis 2009; 19:525-531.
25. Kaitosaari T, Simell O, Viikari J, et al. Tracking and determinants of LDL particle size in healthy children from 7 to 11 years of age: the STRIP Study. Eur J Pediatr 2009; 168:531-539.
26. Kwiterovich PO. Recognition and management of dyslipidemia in children and adolescents. J Clin Endocrinol Metab 2008; 93:4200-4209.
27. Eissa MA, Wen E, Mihalopoulos NL, et al. Evaluation of AAP guidelines for cholesterol screening in youth: Project HeartBeat! Am J Prev Med 2009; 37 (1 Suppl):S71-S77.
28. Lee JM, Gebremariam A, Card-Higginson PC, et al. Poor performance of body mass index as a marker for hypercholesterolemia in children and adolescents. Arch Pediatr Adolesc Med 2009; 163:716-723.
29. US Preventive Services Task Force. Screening for lipid disorders in children: US Preventive Services Task Force recommendation statement. Pediatrics 2007; 120: e215-e219.
30. Juonala M, Viikari J, Kahonen M, et al. Childhood levels of serum apolipoproteins B and A-I predict carotid intima-media thickness and brachial endothelial function in adulthood. J Am Coll Cardiol 2008; 52:293-299.
31. Jolliffe CJ, Janssen I. Age-specific lipid and lipoprotein thresholds for adolescents. J Cardiovasc Nurs 2008; 23:56-60.
32. Manlhiot C, Larsson P, Gurofsky RC, Smith RW, et al. Spectrum and management of hypertriglyceridemia among children in clinical practice. Pediatrics 2009; 123:458-465.
33. Rahalkar AR, Hegele RA. Monogenic pediatric dyslipidemias: classification, genetics and clinical spectrum. Mol Genet Metab 2008; 93:282-294.
34. Beigneux AP, Franssen R, Bensadoun A, et al. Chylomicronemia with a mutant GPIHBP1 (Q115P) that cannot bind lipoprotein lipase. Arterioscler Thromb Vasc Biol 2009; 29:956-962.
35. Korsten-Reck U, Kromeyer-Hauschild K, Korsten K, et al. Frequency of secondary dyslipidemia in obese children. Vasc Health Risk Manag 2008; 4:1089-1094.
36. Sumner AE. Ethnic differences in triglyceride levels and high-density lipoprotein lead to underdiagnosis of the metabolic syndrome in black children and adults. J Pediatr 2009; 155 (S7):e7-e11.
37. Baass A, Dubuc G, Tremblay M, et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem 2009; 55:1637-1645.
38. Gidding SS, Dennison BA, Birch LL, et al. Dietary recommendations for children and adolescents. A guide for practitioners. Consensus statement from the American Heart Association. Circulation 2005; 112:2061-2075.
39. Nemet D, Barkan S, Epstein Y, et al. Short-and long-term beneficial effects of a combined dietary-behavioral-physical activity intervention for the treatment of childhood obesity. Pediatrics 2005; 115:e443-e449.
40. Zappalla FR, Gidding SS. Lipid management in children. Endocrinol Metab Clin N Am 2009; 38:171-183.
41. Iughetti L, Predieri B, Balli F, Calandra S. Rational approach to the treatment for heterozygous familial hypercholesterolemia in childhood and adolescence: a review. J Endocrinol Invest 2007; 30:700-719.
42. Obarzanek E, Kimm SY, Barton BA, et al., DISC Collaborative Research Group. Long-term safety and effects of a cholesterol-lowering diet in children with elevated low-density lipoprotein cholesterol: seven-year result of the Dietary Intervention Study in Children (DISC). Pediatrics 2001; 107:256-264.
43. Talvia S, Lagstrom H, Rasanen M, et al. A randomized intervention since infancy to reduce intake of saturated fat; calorie (energy) and nutrient intakes up to 10 years in the Special Turku Coronary Risk Factor Intervention Project. Arch Pediatr Adolesc Med 2004; 158:41-47.
44. Weghuber D, Widhalm K. Effect of 3-month treatment of children and adolescents with familial and polygenic hypercholesterolemia with a soysubstituted diet. Br J Nutr 2008; 99:281-286.
45. Jakuli L, Vissers MN, Rodenburg J, et al. Plant stanols do not restore endothelial function in prepubertal children with familial hypercholesterolemia despite reduction of low-density lipoprotein cholesterol levels. J Pediatr 2006; 148:495-500.
46. Shafiq N, Singh M, Kaur S, et al. Dietary treatment for familial hypercholesterolemia. Cochrane Database Syst Rev 2010:CD001918.
47. Kelley GA, Kelley KS. Effects of aerobic exercise on non-HDL-c in children and adolescents: a meta-analysis of randomized controlled trials. Prog Cardiovasc Nurs 2008; 23:128-132.
48. de Ferranti S, Ludwig DS. Storm over statins. The controversy surrounding pharmacologic treatment of children. N Engl J Med 2008; 359:1309-1312.
49. O'Gorman CS, Higgins MF, O'Neil MB. Systematic review and meta-analysis of statins for heterozygous familial hypercholesterolemia in children: evaluation of cholesterol changes and side effects. Pediatr Cardiol 2009; 30:482-489.
50. Cox ER, Halloran DR, Homan SM, et al. Trends in the prevalence of chronic medication use in children: 2002-2005. Pediatrics 2008; 122:e1053-e1061.
51. van der Graaf A, Kastelein JJ, Wiegman A. Heterozygous familial hypercholesterolaemia in childhood: cardiovascular risk prevention. J Inherit Metab Dis 2009; 32:699-705.
52. Arambepola C, Farmer AJ, Perera R, Neil HAW. Statin treatment for children and adolescents with heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. Atherosclerosis 2007; 195:339-347.
53. Avis HJ, Vissers MN, Stein EA, et al. A systematic review and metaanalysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2007; 27:1803-1810.
54. Rodenburg J, Vissers MN, Wiegman A, et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation 2007; 116:664-668.
55. de Jongh S, Lilien MR, op't Roodt J, et al. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 2002; 40:2117-2121.
56. Ferreira WP, Bertolami MC, Santos SN, et al. One-month therapy with simvastatin restores endothelial function in hypercholesterolemic children and adolescents. Pediatr Cardiol 2007; 28:8-13.
57. Avis HJ, Vissers MN, Wijburg FA, et al. The use of lipid-lowering drug therapy in children and adolescents. Curr Opin Investig Drugs 2009; 10:224-231.
58. Holmes KW, Kwiterovich PO. Treatment of dyslipidemia in children and adolescents. Curr Card Rep 2005; 7:445-456.
59. Koeijvoets KC, Rodenburg J, Hutten BA, et al. Low-density lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia: substudy of an intima-media thickness trial. Circulation 2005; 112:3168-3173.
60. Hedman M, Miettinen TA, Gylling H, et al. Serum non cholesterol sterols in children with heterozygous familial hypercholesterolemia undergoing pravastatin therapy. J Pediatr 2006; 148:241-246.
61. Stein EA, Marais AD, Szamosi T, et al. Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J Pediatr 2010; 156:231-236.
62. Kalra S, Gandhi A, Kalra B, Agrawal N. Management of dyslipidemia in children. Diabetol Metab Syndr 2009; 1:26-31.
63. Davis HR Jr, Basso F, Hoos LM, et al. Cholesterol homeostasis by the intestine: lessons from Niemann-Pick C1 Like 1 [NPC1L1]. Atherosclerosis 2009; 9:77-81.
64. Gagné C, Gaudet D, Bruckert E, for the Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002; 105:2469-2475.
65. Yeste D, Chacon P, Clemente M, et al. Ezetimibe as monotherapy in the treatment of hypercholesterolemia in children and adolescents. J Pediatr Endocrinol Metab 2009; 22:487-492.
66. Clauss S, Wai K, Kavey RW, Kuehl K. Ezetimibe treatment of pediatric patients with hypercholesterolemia. J Pediatr 2009; 154:869-872.
67. Robinson JG, Davidson M. Is it over for ezetimibe? Expert Rev Cardiovasc Ther 2008; 6:781-783.
68. Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 385:1431-1443.
69. Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359:1343-1356.
70. Iughetti L. Drugs for children with hypercholesterolemia: be cautious. J Pediatr Endocrinol Metab 2009; 22:483-485.